1 Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Do-brinska MR, et al.In-vivo phenotyping for CYP3A by a singlepoint determination of midazolam plasma concentration [J]. Pharmacogenetics, 2001;11(9):781-91
2 Lee JI, Chaves G, Amico JA, Kroboth PD, Wilson JW, Frye RF.Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping[J]. Pharmacogene Genom, 2002;72(6):718-28
3 Gorski JC, Stephen DH, David RJ, Mark VB, Steven AW. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A(CYP3A) subfamily[J].Biochem Pharmacol, 1994;47(9):1643-53
4 Watkins PB.Noninvasive tests of CYP3A enzymes[J].Pharmacogenetics, 1994;4(4):171-84
5 Lane EA, Parashos I.Drug pharmacokinetics and the carbon dioxide breath test[J].Drug pharmacokinet Biopharm, 1986; 14(1):29-49
6 Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, et al.P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients[J].Clin Pharmacol Ther, 1994;56(3):253-60
7 Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK.Urinary excretion of 6[beta]-hydroxycortisol as an in-vivo marker for CYP3A induction:applications and recommendations [J].Clin Pharmacol Ther, 1998;63(6):617-22
8 Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, et al.Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol[J].Clin Pharmacol Ther, 1992;51(1):18-23
9 Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al.Absence of correlation among three putative in-vivo probes of human cytochrome P-4503A4 activity in young healthy men [J].Clin Pharmacol Ther, 1993; 54(6):621-9
10 Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al.Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450 ⅢA (CYP3A) activity[J].Clin Pharmacol Ther, 1992;52(3):265-73
11 Gotzkowsky SK, Kashuba ADM, Hall W, Kulawy RW, Beck DJ, Rocci ML Jr, et al.Poor correlation between 24-hour urinary 6[beta]-hydroxycortisol:cortisol molar ratios(CMR) and plasma midazolam clearance (MDZ CL) as measures of hepatic CYP3A activity[J].Clin Pharmacol Ther, 1999;65(5):167
12 Ndanusa BU, Mustapha A, Abdu-Aguye I.The effect of single doses of rifampicin on the pharmacokinetics of oral nifedipine [J].J Pharm Biomed Anal, 1997;15(9-10):1571-5
13 Kleinbloesem CH, Brummelen P van, Faber H, Danhof M, Vermeulen NPE, Breimer DD, et al.Variability in nifedipine pharmacokinetics:a new oxidation polymorphism in man[J]. Biochem Pharmacol, 1984;33(22):3721-4
14 Schellens JH, Ghabrial H, van der Wart HH, Bakker EN, Wilkinson GR, Breimer DD, et al.Differential effects of qunidine on the disposition of nifedipine, sparteine and mephenytoin in humans[J].Clin Pharmacol Ther, 1991;50(5 pt 1):520-8
15 Cakaloglu Y, Tredger JM, Devlin J, Williams R.Importance of cytochrome P-450 Ⅲ A activity in determining dosage and blood levels of FK 506 and cy closporine in liver transplant recipients[J].Hepatology, 1994;20(2):309-16
16 Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T. The lignocaine metabolite(MEGX) liver function test and P-450 induction in human[J].Br J Clin Pharmacol, 1998;46(6): 535-9
17 Guitton J, Buronfosse T, Desage M, Lepape A, Brazier JL, Beaune P.Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil [J].Biochem Pharmacol, 1997;53(11):1613-9
18 Krivoruk Y, KinironsMT, Wood AJJ, WoodM.Alfentanil disposition in-vivo is mediated by CYP3A4 in human[J].Anesthesiology, 1994;81(6):A380
19 Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K.Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe[J].Anesthesiology, 1997;87(1):26-35
20 Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E.Midazolam is metabolized by at least three different cytochrome P450 enzymes [J].Br J Anaesth, 1994;73(5): 658-61
21 Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al.Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel.Lack of prediction by the erythromycin breath test[J].Drug Metab Dispos, 1994;22 (6):947-55
22 Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al.Use of midazolam as a human cytochrome P450 3A probe:Ⅰ.In vitro-in vivo correlations in liver transplant patients[J].J Pharmacol Exp Ther, 1994;271(1):549-56
23 Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al.The erythromycin breath test predicts the clearance of midazolam[J].Clin Pharmacol Ther, 1995;57 (1):16-24
24 Thummel KE, Shen DD, Bacchi CE, McVicar JP, Marsh CL, Perkins JD, et al.Induction of human hepatic P4503A3/4 by phenytoin[J].Hepatology, 1992;16(6):160A
25 Olkkola KT, Aranko K, Luurila H, Hiller A, Sarnivaara L, Himberg JJ, et al.A potentially hazardous interaction between erythromycin and midazolam[J].Clin Pharmacol Ther, 1993; 53(3):298-305
26 Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C.Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects[J].J Clin Pharmacol, 1989;29(3):272-7
27 Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al.Use of midazolam as a human cytochrome P450 3A probe:Ⅱ.Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation[J].J Pharmacol Exp Ther, 1994;271(1):557-66
28 Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH.Single plasma sampling to predict oral clearance of CYP3A probe mid-azolam[J].Acta Pharmacol Sin, 2001;22(7):634-8
29 王军升, 许振华, 周宏灏.细胞色素P4503A4 与药物氧化代谢[J].中国临床药理学杂志, 1996;12(4):231-5
30 Torben LN, Birgitte BR, Jean-Pierre F, Philippe B, Kim B. In vitro metabolism of quinidine:The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes[J].J Pharmacol Exp Ther, 1999;289(1):31-7
31 Jennifer AL, Gregory LK, Susan MAR, Anne NN, Irim SK, Angela DMK, et al.Cisapride:A potential model substrate to assess cytochrome P4503A4 activity in vivo[J].Clin Pharmacol Ther, 2003;73(3):209-22
32 Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al.Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein[J].Pharmaceu Resea, 1999;16(3):408-14 |
